Oncolytics Biotech Cash Flow Statement Analysis

Operating, investing, and financing activities in millions CAD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Oncolytics Biotech Inc. (ONCY) - Annual data in millions CAD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-31.71-27.75-24.84-26.30-22.51-33.12-17.04
Depreciation & Amortization0.420.400.390.450.450.490.10
Stock Based Compensation2.722.072.383.832.560.000.00
Change in Working Capital3.541.770.39-0.910.21-1.803.89
Change in Accounts Receivable-0.050.510.35-0.781.980.000.00
Change in Accounts Payable1.22-0.081.660.18-1.370.000.00
Change in Other Working Capital0.140.07-0.080.09-0.400.000.00
Other Operating Activities0.14-3.22-0.080.090.070.090.08
Net Cash from Operating Activities-26.97-28.45-23.36-22.43-22.07-19.91-11.92
Investing Activities
Capital Expenditures-0.24-0.01-0.06-0.290.030.01-0.11
Purchases of Investments0.0020.23-20.350.000.000.000.00
Sales/Maturities of Investments0.0020.23-20.350.000.000.000.00
Net Cash from Investing Activities-0.2420.22-20.40-0.29-0.03-0.01-0.11
Financing Activities
Debt Repayment-0.35-0.41-0.38-0.37-0.46-0.450.00
Common Stock Issued6.9231.6212.5732.9138.3018.0013.17
Other Financing Activities-0.750.00-0.76-1.26-1.740.000.00
Net Cash from Financing Activities6.6431.9912.2133.0239.7721.0213.30
Summary
Effect of Forex Changes on Cash1.60-0.521.96-0.25-0.60-0.650.59
Net Change in Cash-20.5723.77-31.5510.3017.680.451.27
Cash at Beginning of Period34.9111.6741.2631.2214.1513.7011.84
Cash at End of Period15.9434.9111.6741.2631.2214.1513.70
Free Cash Flow-27.21-28.46-23.41-22.72-22.07-19.91-12.03
Supplemental Disclosures
Income Taxes Paid0.180.120.050.040.010.010.02